Reducing Stasis Outcomes for Depression in Group Behavioural Activation Therapy
NCT ID: NCT02970279
Last Updated: 2018-05-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2016-12-31
2017-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Behavioural Activation and Severe Learning Disabilities
NCT06851741
Transdiagnostic Behavioral Activation Therapy for Youth Anxiety and Depression
NCT01829100
A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients
NCT04996433
Treatment for Chronic Depression
NCT00204152
Effects of Behavioural Activation on Emotional Cognition and Mood
NCT03995186
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients who access the Improving Access to Psychological Therapies (IAPT) service in Sheffield, United Kingdom with a primary presenting problem of depression and are referred to BAG will be approached to take part in the study. Patients will be asked to provide informed consent to agree for their weekly routine outcome scores from enhanced BAG to be used in the study.
Enhanced BAG Augmentations
The existing BAG treatment will be enhanced with embedded treatment augmentations. The augmentations will consist of two strands; 1) implementation intentions to directly target reducing stasis and 2) psychoeducation to target reducing drop-out.
Implementation Intentions: The first augmentation will be a top-down theoretically informed 'implementation intentions' enhancement to target reducing the stasis outcome rate. Implementation intentions are specific plans about how, when and where goals will be acted upon, formed using an if-then format in order to effectively implement actions. Patients will be taught to use if-then planning (implementation intentions) to help them complete the between-session which is crucial to producing change in BA.
Dose-Response Psychoeducation: The second augmentation will be a dose-response psychoeducation enhancement aimed at reducing the dropout rate. Patients will be given information based on practice-based evidence about the effectiveness of BAG and dose-response information (minimum number of sessions required to experience change).
Treatment Integrity
Treatment adherence to the protocol will be assessed using a BAG adherence checklist created for this trial. Adherence will be checked and compared using self-report and an expert rater; i) after each session the BAG facilitators will complete the session integrity measure to check self-report adherence and ii) the BAG facilitator lead will observe and rate one session from each course of BAG to provide an expert adherence check.
Data Collection
Data collection for the study will run for a year from January 2017 until December 2017 incorporating six BAG treatment groups.
Data Analysis
The data will be analysed using the intention-to-treat (ITT) principle. The final available measure will be used as the post score or if there is only one score available, it will be assumed there was no change. Patients who do not score above the clinical cut-off for depression (score of ≥10 on Patient Health Questionnaire \[PHQ-9\]) prior to commencing BAG will not be included in the analysis to avoid a floor effect when calculating stasis outcomes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enhanced Behavioural Activation Groups
Behavioural activation group (BAG) psychotherapy delivered with two embedded treatment augmentations;
1. Implementation intentions
2. Dose-response psychoeducation
Behavioural Activation Group (BAG) Psychotherapy
Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavioural Activation Group (BAG) Psychotherapy
Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with co-morbid anxiety symptoms can be included as long as depression is the primary diagnosis
* Are referred to and choose the Behavioural Activation Group (BAG) treatment option
* Able to attend the BAG intervention
* Aged 18 or over
Exclusion Criteria
* Patients who do not choose BAG as a treatment option
* Aged under 18
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sheffield Health and Social Care NHS Foundation Trust
UNKNOWN
Howard Morton Trust
UNKNOWN
University of Sheffield
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Melanie Simmonds-Buckley
PhD Research Student
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Melanie K Simmonds-Buckley, BSc
Role: PRINCIPAL_INVESTIGATOR
University of Sheffield
Stephen Kellett, DClinPsy
Role: PRINCIPAL_INVESTIGATOR
University of Sheffield & Sheffield Health and Social Care NHS Foundation Trust
Glenn Waller, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Sheffield
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sheffield Health and Social Care NHS Foundation Trust - Improving Access to Psychological Therapies Service
Sheffield, South Yorkshire, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gollwitzer, P. M. (1999). Implementation intentions: Strong effects of simple plans. American Psychologist, 54, 493-503.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Protocol Version 3.0
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.